Concepedia

Thomas Nydam

TN

Statistics

Publications

3

Citations

374

H-Index

3

Active since

2012

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Thomas Nydam is an author at Novartis (Switzerland) specializing in oncology, medicine, and cancer therapeutics.

Top concepts

MedicineOncologyPharmacologyCancer TherapyRadiation OncologyUrologyCancer ResearchPharmacotherapySurgical OncologyMolecular Oncology

Publications per year

2012–2020

3

Publications

3

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales et al. · The Lancet. Gastroenterology & hepatology · 2020 · 227 citations

Open-label Phase 2, Pancreatic Cancer, Gastrointestinal Oncology +7

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

Dana E. Rathkopf, Joel Picus, Arif Hussain et al. · Cancer Chemotherapy and Pharmacology · 2013 · 91 citations

Urology, Surgical Oncology, Oncology +6

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

Sally Clive, Margaret M. Woo, Thomas Nydam et al. · Cancer Chemotherapy and Pharmacology · 2012 · 56 citations

Oncology, Pancreatic Cancer, Medicine +8

1–3 of 3